132 related articles for article (PubMed ID: 38235681)
1. Cost and effectiveness comparison of sirolimus versus standard treatment in Kasabach-Merritt phenomenon: a real-world evidence study in Thailand.
Tongruang C; Wananukul S; Chatproedprai S; Narkbunnam N; Nitiyarom R; Sirachainan N; Natesirinilkul R; Chaweephisal P; Sosothikul D
Pediatr Hematol Oncol; 2024 Apr; 41(3):229-239. PubMed ID: 38235681
[TBL] [Abstract][Full Text] [Related]
2. Sirolimus for Kaposiform Hemangioendothelioma With Kasabach-Merritt Phenomenon in Two Infants.
Wang Y; Kong L; Sun B; Cui J; Shen W
J Craniofac Surg; 2020 Jun; 31(4):1074-1077. PubMed ID: 32176003
[TBL] [Abstract][Full Text] [Related]
3. Retroperitoneal kaposiform hemangioendothelioma complicated by Kasabach-Merritt phenomenon and obstructive jaundice: A retrospective series of 3 patients treated with sirolimus.
Yao W; Li K; Wang Z; Dong K; Zheng S
Pediatr Dermatol; 2020 Jul; 37(4):677-680. PubMed ID: 32212177
[TBL] [Abstract][Full Text] [Related]
4. Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: A multicenter retrospective study.
Ji Y; Chen S; Xiang B; Li K; Xu Z; Yao W; Lu G; Liu X; Xia C; Wang Q; Li Y; Wang C; Yang K; Yang G; Tang X; Xu T; Wu H
Int J Cancer; 2017 Aug; 141(4):848-855. PubMed ID: 28486787
[TBL] [Abstract][Full Text] [Related]
5. Rapidly enlarging "bruise" on the back of an infant. Kaposiform hemangioendothelioma complicated by Kasabach-Merritt syndrome.
Chan S; Cassarino DS
JAMA Dermatol; 2013 Nov; 149(11):1337-8. PubMed ID: 24005816
[No Abstract] [Full Text] [Related]
6. Development of Kasabach-Merritt phenomenon following vaccination: More than a coincidence?
Ji Y; Chen S; Yang K; Xia C; Peng S
J Dermatol; 2018 Oct; 45(10):1203-1206. PubMed ID: 30118141
[TBL] [Abstract][Full Text] [Related]
7. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon in an infant: Successful treatment with prednisolone, vincristine, and addition of sirolimus.
Cashell J; Smink GM; Helm K; Xavier F
Pediatr Blood Cancer; 2018 Dec; 65(12):e27305. PubMed ID: 30070028
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of transcatheter arterial chemoembolization combined with sirolimus for treating Kasabach-Merritt phenomenon in infants, a retrospective study.
Yin CG; Qi WW; Wang S; Pan D; Chen XL; Li SY
Ann Med; 2023 Dec; 55(1):2196090. PubMed ID: 37038342
[TBL] [Abstract][Full Text] [Related]
9. Sirolimus as initial therapy for kaposiform hemangioendothelioma and tufted angioma.
Wang H; Guo X; Duan Y; Zheng B; Gao Y
Pediatr Dermatol; 2018 Sep; 35(5):635-638. PubMed ID: 29999213
[TBL] [Abstract][Full Text] [Related]
10. Additive value of transarterial embolization to systemic sirolimus treatment in kaposiform hemangioendothelioma.
Brill R; Uller W; Huf V; Müller-Wille R; Schmid I; Pohl A; Häberle B; Perkowski S; Funke K; Till AM; Lauten M; Neumann J; Güttel C; Heid E; Ziermann F; Schmid A; Hüsemann D; Meyer L; Sporns PB; Schinner R; Schmidt VF; Ricke J; Rössler J; Kapp FG; Wohlgemuth WA; Wildgruber M
Int J Cancer; 2021 May; 148(9):2345-2351. PubMed ID: 33231291
[TBL] [Abstract][Full Text] [Related]
11. Effective low-dose sirolimus regimen for kaposiform haemangioendothelioma with Kasabach-Merritt phenomenon in young infants.
Harbers VEM; van der Salm N; Pegge SAH; van der Vleuten CJM; Verhoeven BH; Vrancken SLAG; Schultze Kool LJ; Fuijkschot J; Te Loo DMMWM
Br J Clin Pharmacol; 2022 Jun; 88(6):2769-2781. PubMed ID: 34957601
[TBL] [Abstract][Full Text] [Related]
12. [Refractory kaposiforme hemangioendothelioma in the pediatric population: case report and literature review.].
Gómez-Villegas CP; Pérez-Téllez C; Ochoa-Gaviria J; Builes N
Bol Med Hosp Infant Mex; 2021; 78(4):376-384. PubMed ID: 34351887
[TBL] [Abstract][Full Text] [Related]
13. Sirolimus combined with glucocorticoids in the treatment of Kasabach-Merritt phenomenon in a neonate: A case report.
Cheng J; Zou Y; Fu R; Jin P; Huang M; Wu Z; Bai H; Huang X; Yuan H
Medicine (Baltimore); 2024 Apr; 103(14):e37706. PubMed ID: 38579031
[TBL] [Abstract][Full Text] [Related]
14. Sirolimus Treatment of an Infant With Intrathoracic Kaposiform Hemangioendothelioma Complicated by Life-threatening Pleural and Pericardial Effusions.
Duan L; Renzi S; Weidman D; Waespe N; Chami R; Manson D; Cada M; Carcao M
J Pediatr Hematol Oncol; 2020 Jan; 42(1):74-78. PubMed ID: 30044355
[TBL] [Abstract][Full Text] [Related]
15. Role of Sirolimus in Advanced Kaposiform Hemangioendothelioma.
Oza VS; Mamlouk MD; Hess CP; Mathes EF; Frieden IJ
Pediatr Dermatol; 2016; 33(2):e88-92. PubMed ID: 26864138
[TBL] [Abstract][Full Text] [Related]
16. NEWBORNS WITH KASABACH-MERRITT PHENOMENON-ASSOCIATED KAPOSIFORM HEMANGIOENDOTHELIOMA: A REPORT OF 6 CASES.
Benzar IM; Rebenkov SO; Levytskyi AF; Fedoniuk LY; Fomina LV; Sas LM; Stravskyy TY
Wiad Lek; 2020; 73(8):1785-1789. PubMed ID: 33055352
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of Kasabach-Merritt phenomenon arising from Kaposiform hemangioendothelioma by sirolimus.
Wang Z; Li K; Dong K; Xiao X; Zheng S
J Pediatr Hematol Oncol; 2015 Jan; 37(1):72-3. PubMed ID: 24309604
[No Abstract] [Full Text] [Related]
18. Low dose sirolimus treatment for refractory tufted angioma and congenital kaposiform hemangioendothelioma, both with Kasabach-Merritt phenomenon.
Mariani LG; Schmitt IR; Garcia CD; Kiszewski AE
Pediatr Blood Cancer; 2019 Aug; 66(8):e27810. PubMed ID: 31087627
[No Abstract] [Full Text] [Related]
19. A not so harmless mass: Kaposiform hemangioendothelioma complicated by a Kasabach-Merritt phenomenon.
Tribolet S; Hoyoux C; Boon LM; Cheruy C; Demarche M; Jamblin P; Roberti A; Willemaers V; Viellevoye R; Rigo V; Broux I
Arch Pediatr; 2019 Sep; 26(6):365-369. PubMed ID: 31353149
[TBL] [Abstract][Full Text] [Related]
20. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon: from vincristine to sirolimus.
Jahnel J; Lackner H; Reiterer F; Urlesberger B; Urban C
Klin Padiatr; 2012 Oct; 224(6):395-7. PubMed ID: 23070861
[No Abstract] [Full Text] [Related]
[Next] [New Search]
